A deadly drug-resistant fungus is silently spreading through UK hospitals, threatening vulnerable patients while defying standard medical treatments.
Story Overview
- Candida auris fungus spreads rapidly in UK hospitals, colonizing groin and armpit areas
- Pathogen resists multiple antifungal drugs with mortality rates reaching 62% in severe cases
- European cases surged to 1,346 in 2023 alone, with UK reporting fewer than 700 total cases
- Environmental persistence on surfaces and medical equipment complicates infection control efforts
UK Hospitals Face Growing Threat
Candida auris presents an escalating challenge to British healthcare facilities, with the UK Health Security Agency confirming ongoing outbreaks across multiple hospital systems. The fungus demonstrates alarming persistence on hospital surfaces and medical equipment, making traditional cleaning protocols insufficient. UKHSA reports fewer than 700 cases detected to date, but experts warn this likely represents significant underreporting due to diagnostic difficulties and surveillance gaps.
Hospital intensive care units face particular vulnerability, as critically ill and immunocompromised patients provide ideal conditions for fungal colonization. The pathogen’s preference for warm, moist areas like the groin and armpits creates additional challenges for infection control teams attempting containment measures.
Watch:
Multidrug Resistance Undermines Treatment Options
The fungus exhibits resistance to fluconazole and variable resistance to echinocandins and amphotericin B, leaving clinicians with limited therapeutic options. This resistance profile forces healthcare providers to rely on expensive, toxic antifungal combinations that may prove ineffective. Academic researchers emphasize the urgent need for susceptibility testing and development of new antifungal agents as existing treatments fail against evolving resistance mechanisms.
Mortality rates range from 29% to 62% in severe cases, reflecting both the pathogen’s virulence and the limitations of available treatments. The World Health Organization designated Candida auris as a fungal priority pathogen, recognizing its potential to overwhelm healthcare systems worldwide through resistance and outbreak potential.
European Surge Signals Broader Crisis
The European Centre for Disease Prevention and Control documented a sharp increase in cases, with 1,346 reported across EU countries in 2023 compared to steady lower numbers in previous years. Greece, Italy, and Spain now report regional or national endemicity, indicating the fungus has established permanent presence in their healthcare systems. New outbreaks emerged in Cyprus, France, and Germany during 2023, demonstrating continued geographic expansion.
Drug-resistant fungus is now spreading across the UK – and it attacks the groinhttps://t.co/HPXylTwxNv pic.twitter.com/7RXm9A3g4Q
— The Mirror (@DailyMirror) November 25, 2025
Dr. Diamantis Plachouras of the ECDC emphasizes the need for early detection and coordinated infection control measures across European healthcare networks. The organization calls for urgent action to prevent further spread, warning that gaps in national surveillance and infection prevention guidance leave healthcare systems vulnerable to larger outbreaks that could prove difficult to contain.
Sources:
Drug-resistant fungus Candidozyma auris confirmed to spread rapidly in European hospitals
Multidrug-resistant yeast cases rising rapidly in Europe, survey shows
What is Candidozyma auris? A fungal pathogen and emerging global health threat
Candida auris: a fungus with identity crisis
